Cargando…
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637638/ https://www.ncbi.nlm.nih.gov/pubmed/23594799 http://dx.doi.org/10.1186/2045-3329-3-6 |
_version_ | 1782475773997744128 |
---|---|
author | Vincenzi, Bruno Frezza, Anna Maria Schiavon, Gaia Santini, Daniele Dileo, Palma Silletta, Marianna Delisi, Delia Bertoldo, Francesco Badalamenti, Giuseppe Baldi, Giacomo Giulio Zovato, Stefania Berardi, Rossana Tucci, Marco Silvestris, Franco Dei Tos, Angelo Paolo Tirabosco, Roberto Whelan, Jeremy Simon Tonini, Giuseppe |
author_facet | Vincenzi, Bruno Frezza, Anna Maria Schiavon, Gaia Santini, Daniele Dileo, Palma Silletta, Marianna Delisi, Delia Bertoldo, Francesco Badalamenti, Giuseppe Baldi, Giacomo Giulio Zovato, Stefania Berardi, Rossana Tucci, Marco Silvestris, Franco Dei Tos, Angelo Paolo Tirabosco, Roberto Whelan, Jeremy Simon Tonini, Giuseppe |
author_sort | Vincenzi, Bruno |
collection | PubMed |
description | BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1–9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1–14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting. |
format | Online Article Text |
id | pubmed-3637638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36376382013-04-28 Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options Vincenzi, Bruno Frezza, Anna Maria Schiavon, Gaia Santini, Daniele Dileo, Palma Silletta, Marianna Delisi, Delia Bertoldo, Francesco Badalamenti, Giuseppe Baldi, Giacomo Giulio Zovato, Stefania Berardi, Rossana Tucci, Marco Silvestris, Franco Dei Tos, Angelo Paolo Tirabosco, Roberto Whelan, Jeremy Simon Tonini, Giuseppe Clin Sarcoma Res Research BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1–9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1–14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting. BioMed Central 2013-04-17 /pmc/articles/PMC3637638/ /pubmed/23594799 http://dx.doi.org/10.1186/2045-3329-3-6 Text en Copyright © 2013 Vincenzi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Vincenzi, Bruno Frezza, Anna Maria Schiavon, Gaia Santini, Daniele Dileo, Palma Silletta, Marianna Delisi, Delia Bertoldo, Francesco Badalamenti, Giuseppe Baldi, Giacomo Giulio Zovato, Stefania Berardi, Rossana Tucci, Marco Silvestris, Franco Dei Tos, Angelo Paolo Tirabosco, Roberto Whelan, Jeremy Simon Tonini, Giuseppe Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
title | Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
title_full | Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
title_fullStr | Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
title_full_unstemmed | Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
title_short | Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
title_sort | bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637638/ https://www.ncbi.nlm.nih.gov/pubmed/23594799 http://dx.doi.org/10.1186/2045-3329-3-6 |
work_keys_str_mv | AT vincenzibruno bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT frezzaannamaria bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT schiavongaia bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT santinidaniele bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT dileopalma bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT sillettamarianna bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT delisidelia bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT bertoldofrancesco bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT badalamentigiuseppe bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT baldigiacomogiulio bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT zovatostefania bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT berardirossana bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT tuccimarco bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT silvestrisfranco bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT deitosangelopaolo bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT tiraboscoroberto bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT whelanjeremysimon bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions AT toninigiuseppe bonemetastasesinsofttissuesarcomaasurveyofnaturalhistoryprognosticvalueandtreatmentoptions |